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The Implications of 
Reused Medical  
Devices 
By Christina Hage 
hagechri@shu.edu 
An increasing number of U.S. 
hospitals are saving money by 
reusing medical devices origi-
nally approved for only one-
time use, thereby ignoring the 
warnings posted by the manu-
facturers of such devices.   
The Food and Drug Admini-
stration defines a medical 
device as “any health care 
product that does not achieve 
its primary intended purpose 
by chemical action or by being 
metabolized.”  
Some medical devices are 
classified as single-use devices 
(SUDs).  SUDs are considered 
by the manufacturer to only 
be safe for a one-time use and 
must  be discarded after being 
used. However, hospitals have 
implemented procedures to 
reprocess some of these 
SUDs.  
Examples of SUDs that are 
currently being reprocessed 
include surgical drills, biopsy 
forceps, electrophysiology 
catheters, cartilage knives, 
trocars, and laparoscopy scis-
sors. 
Hospitals are not required to 
inform patients that they may 
receive a device that the hos-
pital has chosen to reuse 
against the manufacturer’s 
recommendation.   Currently, 
three out of four surgeons 
believe that reprocessing  
See “Savings” on Page 9 
An Increase in Savings, a Decrease in Safety 
Mental Health Parity 
The Next Step in the 
Mental Health      
Revolution 
By Shelly Weizman 
weizmash@shu.edu  
The concept of “mental 
health parity” refers to a re-
quirement that health benefits 
companies, including man-
aged care and insurance com-
panies, provide the same in-
surance coverage for mental 
health treatment that they 
provide for other medical 
treatments. 
Under most health benefits 
plans, there is a dramatic dis-
parity in coverage between 
mental and physical health 
services. The goal of the men-
tal health parity initiative is to 
eliminate this disparity 
through legislation that man-
dates equal coverage for all 
health services.  While oppo-
nents of parity argue cost as a 
reason for denial of coverage, 
proponents of an equal sys-
tem argue that the practice of 
See “Parity” on Page 6 
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The Controversy Over  
Proposed Limits 
By Sarah Geers 
geerssar@shu.edu 
The pharmaceutical industry, com-
prised of both “innovator” and 
“generic” drug companies, plays a 
significant role in the American health 
care system.  However, the dazzling 
scientific achievements that enable the 
development of new drugs are only 
possible when sandwiched between 
two cornerstones of the system: the 
public health safeguards of the FDA’s 
regulatory process and the economic 
safeguards of the United States patent 
system.   
A strong patent system provides in-
centives to innovator drug companies 
to invest in the risky, lengthy, and 
expensive drug discovery process, 
while the later expiration of the pat-
ents (combined with FDA review and 
approval) allows generic drug compa-
nies to benefit from the discovery and 
clinical foundation laid by the innova-
tors.  The American public ultimately 
benefits from the tension between 
innovation and commoditization that 
our patent system encourages. 
The Debate: The USPTO vs. GSK 
and “Big Pharma” 
In this system, the United States Pat-
ent and Trademark Office (USPTO) is 
responsible for reviewing patent appli-
cations and granting patents, as well as 
creating the rules that govern this 
process.  Recently, the USPTO issued 
final administrative rule changes that  
 
 
 
 
 
 
 
 
significantly altered these patent 
prosecution procedures, which were 
set to take effect on November 1, 
2007. The most significant rule 
changes target the number of claims 
allowed in each patent application and 
the number of subsequent related 
applications allowed.  The implemen-
tation of these new rules is expected 
to significantly alter this economic 
balance between research-based and 
generic drug companies. 
Representing the “Big Pharma” per-
spective in the debate is GlaxoSmith-
Kline (GSK), which has vigorously 
opposed the rule changes by filing suit 
against the USPTO in federal court to 
enjoin the implementation of the new 
requirements.  The USPTO continues 
to defend the rule changes (and pre-
sumably generic company interests) 
while GSK aggressively defends the 
status quo.  A comparison of historical 
practices and the proposed revisions 
highlights what is at stake for these 
parties. 
The New Claims and Applications 
Requirements 
A “claim” is the portion of the patent 
that specifically describes the claimed 
invention, in essence carving out the 
exact invention space to which the 
applicant claims exclusivity.  While a 
patent application may discuss a broad 
or far-reaching innovation, the inven-
tor is required to specify the exact 
scope of the protection he or she 
seeks, usually in the form of a list of 
discrete sub-units of all possible varia-
tions of the invention conceived.  The 
previous USPTO practice allowed an 
unlimited number of claims in the 
application, but the proposed rules 
will cap applicant claims at twenty-five 
(five independent claims, and twenty 
dependent claims, i.e., claims that are 
smaller sub-sets of and hence 
“dependent” on the independent 
claims for their focus). 
The current USPTO patent applica-
tion practice also has a number of 
ways in which an applicant may con-
tinue the subject matter of the original 
application in further applications.  
These continuing applications may be 
fi led for strategic (portfolio-
enhancing) reasons or due to difficul-
ties expected or encountered in the 
application process.  Previously, con-
tinuing applications were not limited, 
but the new rules impose a cap of two 
continuing applications and one re-
quest for continuing examination. 
Expected Impact of Changes in the 
Health Law Field 
The expected impact of these changes 
on the health law field is expansive, as 
characterized by the strong objections 
from major brand-name pharmaceuti-
cal companies, led by GSK.  In its 
ongoing suit against the USPTO, GSK 
alleges that the new rules extend be-
yond its rulemaking authority, effect-
ing a substantive rather than proce-
dural rule change. Apart from ques-
tioning the legality of the rule changes, 
GSK also attacks the changes as being  
See “Patent Practices” on Page 10 
“THE EXPECTED 
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CHANGES IS 
EXPANSIVE, AS 
CHARACTERIZED BY 
STRONG 
OBJECTIONS FROM 
MAJOR 
PHARMACEUTICAL 
COMPANIES” 
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is controversial among patient groups, 
healthcare workers, pharmaceutical 
companies, and government agencies. 
The FDA claims that widespread ac-
cess to unapproved drugs may disturb 
the balance of risks and benefits pro-
tected by the current approval system. 
Phase I studies are performed on a 
small patient population with the pri-
mary purpose of determining maxi-
mum safety limits.  
Phase II studies test the experimental 
drug’s efficacy within a larger patient 
population, often revealing severe 
adverse reactions that Phase I studies 
did not expose.  
Phase III studies determine the statis-
tical significance of drug efficacy by 
further expansion of patient popula-
tions using the most effective dose 
determined in Phase II studies.  
Opponents of the ACCESS Act 
 
The FDA claims that allowing patients 
access to experimental drugs after 
Phase I studies not only poses great 
safety concerns, but may also give 
patients a false hope of a cure.  Simi-
larly, the United States Society for 
Clinical Trials opposes the ACCESS 
Act, claiming the Act undermines sci-
entifically valid testing of new drugs.  
Although the proposed law provides 
more treatment choices, patients and 
their physicians are less informed re-
garding safety and effectiveness of 
these drugs. Patients may receive less 
effective treatments or may be subject 
to severe or unforeseen adverse ef-
fects.  Clinical trials designed to deter-
mine efficacy depend on placebo arms 
for accurate analysis.  Early access 
without the use of placebos threatens 
any evidence of efficacy drug trials 
would attempt to prove.  
 
Proponents of the ACCESS Act 
 
Supporters of the ACCESS Act be-
lieve there are serious concerns about 
the FDA’s drug approval process, 
especially the speed of drug approval.  
Currently, patients may receive experi-
mental drugs before market approval 
through the FDA’s “compassionate 
use” program. This program grants 
seriously ill patients access to  
See “ACCESS Act” on Page 7 
Earlier Access to  
Experimental Drugs 
By Nicole Ho 
honicole@shu.edu 
On November 3, 2005, Senator Sam 
Brownback (R-KS) introduced the 
Access, Compassion, Care and Ethics 
for Seriously-Ill Patients Bill (ACCESS 
Act) in the Senate (S. 1956).  The Act 
proposes a new approval process for 
experimental drugs, allowing earlier 
access for seriously-ill patients who 
have exhausted other treatment op-
tions.  
Under this bill experimental drugs 
would be available to patients after 
completion of Phase I clinical trials. 
Additionally, the bill would remove 
the placebo arm from all clinical trial 
designs.  The proposed ACCESS Act 
The ACCESS Act and Its Effect on the FDA Mission 
Changing How the  
Government Prices Drugs 
By Marc Adler                                 
adlermar@shu.edu 
Recent changes in the way the federal 
healthcare programs of Medicare and 
Medicaid price prescription drugs im-
pact everyone who makes, consumes, 
sells, or prescribes prescription drugs.  
In order to alleviate concerns that 
Medicare and Medicaid have been 
overpaying for drugs due to inaccurate 
pricing by drug companies, the federal 
government established new pricing 
mechanisms and payment formulas 
for prescription drugs.  These shifts in 
the drug pricing system are expected 
to save the government billions of 
dollars over the next several years by 
lowering healthcare costs; however, 
the shifts will also create a ripple effect 
which drastically changes the future of 
the healthcare industry. 
Before the new pricing systems were 
implemented, Medicare and Medicaid 
paid for drugs based on the “average 
wholesale price” (AWP) of the pre-
scription drug, minus five percent of 
the cost of the drug.  AWP was in-
tended to represent the average price 
at which wholesalers (who purchase 
drugs from manufacturers) sell drugs 
to physicians, pharmacies and other 
customers.  
The AWP of a drug was commonly 
referred to as “Ain’t What’s Paid,” 
because it was not an accurate reflec-
tion of the market price of a drug 
Rather, AWP more closely resembled 
a “list price” or “sticker price” because 
it is established from self-reported 
See “Meta-Care” on Page 8 
‘Meta-Care’ and ‘Meta-Caid’ 
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The New Jersey Commission 
on Rationalizing Health Care 
Resources Releases its Final 
Report 
By Kathleen M. Boozang, Profes-
sor of Law, Seton Hall Law School 
On January 24, 2008, the New Jersey 
Commission on Rationalizing Health Care 
Resources, created by Governor Jon 
Corzine fifteen months earlier, and 
chaired by internationally renowned 
health economist Uwe E. Reinhardt, 
Ph.D., released its final Report on 
New Jersey’s ailing healthcare system, 
focusing particularly on the state’s 
financially distressed hospitals.   
The Report comes as Governor Corz-
ine attempts to negotiate the state 
through a variety of unappealing op-
tions to reduce its $32 billion debt.  
New Jersey’s current $3 billion budget 
short-fall is the third highest in the 
nation, following New York and Cali-
fornia.  Given this state of financial 
affairs and the fact that unlike a similar 
commission in New York, the New 
Jersey Commission was created by 
executive order rather than statute, no 
one expects quick fixes. Consequently, 
the Commission’s recommendations 
are just that, and therefore require 
legislative enactment, regulatory adop-
tion, or voluntary implementation to 
take effect. 
The Commission’s Findings 
The New Jersey Commission did not 
target specific hospitals for closure, 
instead developing a framework for 
identifying which financially distressed 
hospitals should receive state support.  
The past fifteen years have seen 
twenty-one hospital closures in New 
Jersey; there have been five hospital 
bankruptcies in New Jersey since July 
2006.  All expectations are that more 
closures will come – over half of the 
state’s remaining seventy-nine acute 
care hospitals are losing money.  In 
2008, two urban hospitals in North 
Jersey, where the most seriously dis-
tressed hospitals are located, have 
already notified the state of their clo-
sure plans.  Low margins and low cash 
on hand represent only a part of the 
landscape of New Jersey’s distressed 
hospitals.  A median long-term debt to 
capitalization ratio of 52.5% precludes 
hospitals from investing in infrastruc-
ture, which has resulted in a very high 
average age of plant and limited in-
vestment in IT infrastructure. 
Most of the Commission’s findings 
were of little surprise to close observ-
ers of the New Jersey healthcare mar-
ket, including that hospital services are 
utilized at a very high rate, typified by 
the fact that chronically ill Medicare 
beneficiaries see more physicians in a 
year than those in any other state in 
the nation.  While New Jersey is over-
bedded, the surplus is not as dramatic 
as that of other states and therefore 
does not explain the extraordinary 
excess in services or the hospitals’ 
uniquely challenging financial woes.  
Neither can the state’s financial chal-
lenges be attributed to differences in 
New Jersey’s population — according 
to the Report, “New Jersey residents 
are not poorer, older or more heavily 
uninsured than the rest of the nation.”  
Nonetheless, the state’s one million 
uninsured, as well as its vulnerable 
populations, encounter deficiencies in 
extant primary and specialty care, es-
pecially treatment for mental health 
and substance abuse. 
Ultimately, the Report attributes hos-
pitals’ financial state to a number of 
factors, with a primary focus on the 
economic system in which hospitals 
operate.  Specifically, the inability of 
hospitals to exercise control over phy-
sicians’ use of resources, gross under-
payment by public payers, the overall 
pricing system employed by the indus-
try (as among hospitals as well as be-
tween hospitals and ambulatory cen-
ters) and insurers, and, in some cases, 
poor governance by hospital boards.  
Ambulatory care facilities also present 
competitive challenges to hospitals, 
which are exacerbated by the less on-
erous regulatory environment in which 
ambulatory surgical centers in particu-
lar operate.       
The Commission’s                      
Recommendations 
As would be expected, how to strate-
gically respond to the plight of finan-
cially distressed hospitals became the 
major focus of the Commission’s rec-
ommendations to Governor Corzine.  
The Report concludes that insolvent 
non-essential hospitals should be al-
lowed to close, albeit with procedures 
to protect the employees and commu-
nity.   
To implement its recommendation 
that the State should provide financial 
support to “hospitals that are more 
essential and less financially viable,” 
the Commission proposes a formula 
to balance metrics of a hospital’s 
“essentiality” against metrics of its 
financial viability.  In developing this 
approach, the New Jersey Commis-
sion borrowed in some respects from 
the tact employed by the New York 
Commission on Health Care Facilities in the 
21st Century.  As such, the New Jersey 
Commission adopted three criteria for 
analyzing a hospital’s essentiality:  1) 
care for financially vulnerable popula-
tions; 2) provision of essential services  
and 3) utilization. The criteria for fi-
nancial viability  
See “Rationalizing” on Page 5 
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lic on the entities’ web pages.  Patients 
would have access to ambulatory cen-
ters’ charge masters as well as hospi-
tals’ general pricing scheme and its fee 
schedule and collection practices for 
the uninsured.  The Commission also 
recognized the necessity of access to 
data to improve efficiencies in the 
acute care setting.  As such, it recom-
mends that the state collaborate with 
industry to acquire and adapt software 
to be employed throughout the state 
to enable hospitals to track, and report 
to both physicians and the state, the 
average cost of care for each in-patient 
of every physician.     
The Commission also focused on rec-
ommendations to facilitate identifica-
tion and management of a wide range 
of conflicts of interest.  At least one 
set of conflicts, such as an attorney 
serving in the dual capacities of coun-
sel and director, is sought to be 
banned. The Commission recom-
mends managing others, by, for exam-
ple, recommending that physicians be 
required to disclose certain investment 
interests to patients, and that hospital 
boards receive information about 
charitable contributions from vendors 
and contractors. 
Quality of governance received signifi-
cant attention from the Commission, 
with resultant recommendations fo-
cusing on the process by which boards 
are comprised, a requirement of board 
training (which had previously become 
law in New Jersey), and a push for 
transparency between management 
and the board.   
Acknowledging that many hospitals 
have incorporated relevant portions of 
Sarbanes-Oxley into their corporate 
policies, the Commission also ob-
served that a fair number of boards 
have been static in both their compo-
sition and practices for many years, 
contributing to their hospitals’ inability 
to respond to the dynamism of the 
market and the challenges of the in-
dustry.  
The Commission Report takes two 
approaches to improve governance:  
best practices and regulation.  Recom-
mended regulations seek to require 
boards to advertise open positions, 
with an eye towards soliciting directors 
with particular expertise or who cover 
unrepresented constituencies, e.g., the 
community or employees.  Proposed 
regulations would also require the 
existence of audit and compensation 
committees with clear powers that 
closely resemble practices in the for-
profit sector, as well as creation of 
document destruction and retention 
and conflict of interest policies.  Sug-
gested best practices include requiring 
directors to participate in orientation 
and training, ensuring that directors 
receive the entity’s organic corporate 
documents as well as its most recent 
annual reports and financial state-
ments, 990’s, and information about 
leadership at the corporate and hospi-
tal level, and involving the board in 
approving management’s selection of 
legal counsel.    
In several areas, the Report recom-
mends further state commission stud-
ies tp produce approaches to improv-
ing health care delivery practices in the 
state.  So, for example, the Commis-
sion recommends retention of  
See “Rationalizing” on Page 12 
include profitability asmeasured by 
operating margin, liquidity as meas-
ured by cash on hand, and capital 
structure as measured by long-term 
debt to capitalization.  The Report 
also enumerates several non-
quantitative factors to be considered 
in assessing State support, including, 
inter alia, alternative sources of services 
for the community, whether the hos-
pital is part of a system that can pro-
vide additional resources, quality of 
care and efficiency, and impact on 
employment in the area. 
A hospital’s receipt of state support 
through a “Distressed Hospital Pro-
gram” should be accompanied by 
monitoring of efficiency, quality, and 
overall financial health, according to 
the Report.  Apparently, the monitor-
ing would occur in part through the 
provision of a seat on the hospital’s 
board to a state appointee.  The Re-
port also recommends that the De-
partment of Health and Senior Ser-
vices institute an Early Warning Sys-
tem for hospitals with evidence of 
financial distress while there is still 
time remaining to implement a turn-
around plan.  If closure nonetheless 
results, the Report anticipates state 
financial support to cover closing 
costs. 
The remainder of the Commission’s 
recommendations follows several 
broad themes.  Transparency domi-
nates proposed new regulation of am-
bulatory centers, hospitals and physi-
cians, with a focus on access to infor-
mation related to quality, pricing, con-
flicts of interest, and institutional gov-
ernance and financial health.  As con-
ceived by the Commission, the public 
would have access to quality data 
ranging from physician report cards to 
hospitals’ infection rates, sentinel 
events and quality outcomes.  Hospi-
tals’ governance documents, 990s 
(annual reporting forms that tax-
exempt hospitals must file with the 
IRS), board composition and meeting 
minutes would be available to the pub-
Rationalizing, Continued... 
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denying coverage for necessary mental 
health care must end.  
Mental Health Disparity 
In any given year, twenty-six percent 
of adults and over twenty percent of 
children have or will have a diagnos-
able mental or addictive disorder.  
Despite these statistics, only forty-one 
percent of people with a mental illness 
receive treatment and almost four out 
of five children who have a mental 
illness are not receiving mental health 
services. 
One major reason for the lack of treat-
ment is inadequate and discriminatory 
insurance coverage of mental health 
services.  In fact, eighty-seven percent 
of health plans place limits on mental 
health coverage that they do not place 
on medical or surgical care.  Conse-
quently, most people — even people 
who have coverage for mental health 
conditions — find it much more ex-
pensive to receive treatment for men-
tal illness than to receive treatment for 
other illnesses or injuries.  
Inadequacy of Current State and 
Federal Legislation  
Most states have laws requiring some 
form of parity in coverage; however, 
these laws cannot comprehensively 
mandate parity due to restrictions 
found in the Employee Retirement 
Income Security Act (ERISA).  Under 
ERISA, employees that are the benefi-
ciaries of “self-insured” health benefits 
plans are categorically excluded from 
state parity laws.  Under such plans, 
the employer becomes the provider of 
 
 
 
 
 
 
 
 
health benefits and takes the primary 
risk of providing benefits.  
All large multi-state employers and 
many medium single-state employers 
now self-insure. Only the national 
government has the authority to regul- 
See “Parity” on Page 7  
Parity, Continued... 
Common Disparities in  
Mental Health Coverage: 
?? Higher co-pays 
?? Limits on the number of       
outpatient visits 
?? Limits on the number of       
inpatient hospital days covered 
?? Lower quality measures 
Provisions House Bill (H.R. 1424) Senate Bill (S. 558) 
Prohibitions or         
Requirements 
Prohibits treatment limitations or financial re-
quirements not similarly imposed on other medi-
cal benefits (same co-pays, deductibles, etc.) 
Requires plans to provide financial require-
ments and treatment limitations that are no 
more restrictive than those of all the other 
benefits (same co-pays, deductibles, etc.) 
Minimum Benefit    
Requirement 
Same mental health coverage that is offered to 
federal employees 
No minimum benefit requirement 
Definition of      
“Mental Illness” 
All conditions listed in the Diagnostic and Statis-
tical Manual (DSM-IV) 
Health plans may define if no definition is 
advanced by the state 
Self-Insured Coverage Covers self-insured plans Covers self-insured plans 
Preemption Provision Explicitly protects stronger state parity laws No preemption provision 
Mental Health        
Coverage Mandate 
No mandate - only covers plans that provide any 
mental health coverage at all 
No mandate  - only covers plans that provide 
any mental health coverage at all 
Small Employer        
Exemption 
Excludes employers with 50 employees or less Excludes employers with 50 employees or 
less 
Cost Exemption Exempts plans whose costs of compliance in-
creases total costs of coverage by 2% 
Exempts plans whose costs of compliance 
increases total costs of coverage by 2% 
Status of Bill as of 3/25/08 Passed House on March 5, 2008 Passed Senate on September 18, 2007 
“TWENTY-SIX 
PERCENT OF 
ADULTS AND OVER 
TWENTY PERCENT 
OF CHILDREN HAVE 
A MENTAL OR 
ADDICTIVE 
DISORDER” 
Original Chart by Shelly Weizman 
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proved cancer drugs. The FDA even-
tually approved Erbitux for the same 
type of cancer that killed Abigail. At 
the time of Abigail’s request, however, 
Phase II studies, designed to deter-
mine efficacious dosing, had not been 
completed. The FDA was concerned 
that if Abigail had been given Erbitux, 
her physician would have run the risk 
of administering too high or too low a 
dose, with no guarantee of recovery. 
The Abigail Alliance sued the FDA, 
claiming that denial of experimental 
drugs violates a patient’s constitutional 
right.  On appeal, the D.C. Circuit 
held, eight to two, that there is no 
fundamental right grounded in the 
Constitution to grant access to investi-
gational drugs. The United States Su-
preme Court subsequently denied 
certiorari on this case.  
Looking Forward 
The solution to this controversy may 
be a middle-ground compromise. The 
FDA has addressed some of these 
unapproved drugs after completion of 
Phase II clinical trials. However, late-
stage cancer patients may die while 
waiting for compassionate use ap-
proval by the FDA. Supporters of the 
Act also oppose the current clinical 
trial design mandated by the FDA. 
Patients are often excluded from clini-
cal trials because of the strict admis-
sion requirements. Even if patients 
succeed in being admitted into a clini-
cal trial, they may receive a placebo 
rather than the active drug. Many sup-
porters of the ACCESS Act find this 
practice unethical.  
The Abigail Alliance for Better Access 
to Experimental Drugs (Abigail Alli-
ance), a patient advocate group, fully 
supports Senator Brownback’s AC-
CESS Act. The Abigail Alliance argues 
that decisions to use experimental 
drugs should be between a patient and 
his/her physician. The Abigail Alli-
ance emerged when the FDA denied 
Abigail Burroughs access to unap-
concerns by proposing to amend its 
regulations on access to experimental 
drugs. The proposed regulations grant 
access to unapproved drugs during 
emergencies and for increased number 
of patients to be allowed in each trial. 
However, patients would still be re-
quired to exhaust all other treatment 
options.  
This proposal attempts to balance the 
benefits of expanded access with the 
risks involved in pre-Phase II access. 
At the core of this issue is the ques-
tion of how the FDA can save thou-
sands of people suffering from termi-
nal illnesses. The only way to ensure 
the successful approval of safe and 
effective drugs is to perform properly-
controlled clinical trials.  The ACCESS 
Act’s passage will defeat the FDA’s 
mission of approving safe and effec-
tive drugs, something that the FDA 
has been working towards for over 
100 years.  
See Page 13 for Citations 
ACCESS Act, Continued... 
ate these plans.  Since about half of 
the people who have health benefits 
through their employers are covered 
by self-insured plans, only half the 
people with health insurance actually 
benefit from state parity laws.  As 
such, a comprehensive federal parity 
law is the only effective method of 
reaching employees in these plans and 
mandating far-reaching coverage of 
mental health services in all health 
benefits plans. 
While one federal parity law, the Men-
tal Health Parity Act of 1996, currently 
exists, the law inadequately addresses 
disparities in mental health coverage 
because qualified health plans are only 
required to provide parity with regard 
to limits on covered annual and life-
time costs. 
A Federal Law – The Only       
Comprehensive Solution 
Due to the limited reach of current 
federal and state laws, two federal 
parity bills were introduced in Con-
gress in 2007, one in the House and 
the other in the Senate.   
Many mental health advocates favor 
the House bill, which is clearly the 
more extensive of the two.  The Sen-
ate bill, lauded as a compromise be-
tween mental health advocates and the 
business community, contains numer-
ous restrictions and raises multiple 
concerns among some proponents. 
Both bills have passed their respective 
houses and negotiations to construct a 
mental health parity bill acceptable to 
both chambers of Congress will likely 
resume in the next Congressional ses-
sion, which begins in 2009. One of the 
main areas to be agreed upon is the 
minimum benefit standard. 
This nation has made huge strides in 
the areas of mental health rights over 
the past several decades, but there is 
still much more that needs to be ac-
complished. Disparity in coverage is 
unconscionable in a country with such 
rich and vast health care resources. 
The passage of federal mental health 
parity legislation is the next logical 
step forward on the road to reform. 
See Pages 12-13 for Citations 
Parity, Continued... 
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manufacturer data that was not truly 
defined by any laws or regulations.  
Therefore, drug manufacturers were 
free to set the AWP at any level, re-
gardless of the actual market prices 
paid by physicians and suppliers who 
pay for the products. 
In response to reports of fraudulent 
activity and the abuse of Medicare 
reimbursement under the old AWP 
system, the government adopted two 
new pricing systems — one for Medi-
care Part B (which covers physician 
visits) and one for all prescription 
drugs under Medicaid.   
The average sales price (ASP) drug 
pricing system, which was adopted 
along with the Medicare Prescription 
Drug, Improvement and Moderniza-
tion Act of 2003, applies to Medicare 
Part B covered drugs and biologics 
(referred to collectively as “drugs”).  
These drugs are not usually purchased 
at retail pharmacies; rather, healthcare 
providers — such as physicians — 
buy these drugs and then bill Medicare 
after they administer the drugs to pa-
tients. 
The second new pricing system is the 
revised average manufacturer price 
(AMP) system.  Unlike the ASP sys-
tem, the revised AMP rule applies to 
all drugs which may be sold in the 
United States at retail pharmacies.  
Another important distinction be-
tween ASP and AMP is that AMP 
applies to the reimbursement for 
drugs under Medicaid, and not Medi-
care Part B.   
Despite the fact that the ASP and 
AMP systems are quite different, both 
systems reflect the government’s de-
sire to create more accurate drug 
prices and reduce overpayments made 
by its healthcare programs. 
It is important to remember, however, 
that these pricing mechanisms only 
apply to government reimbursement 
under Medicare Part B or Medicaid 
and not to the reimbursement for 
private payers such as health plans.  
Nevertheless, the shifts in reimburse-
ment are significant because of the 
effect that these pricing methodolo-
gies may have on private payers in the 
near future.  In fact, a recent survey 
shows that in 2007, approximately half 
of the health plans surveyed intended 
to use the ASP system for pricing the 
same drugs which are covered under 
Medicare Part B.  Similarly, the AMP 
system is likely to have a more expan-
sive effect since private payers will 
likely adopt AMP as a more reliable 
and inexpensive pricing benchmark 
for all other drugs.  
Therefore, given the potential impact 
of the ASP and revised AMP drug 
reimbursement systems, three ques-
tions need to be addressed in order to 
evaluate the suitability of these monu-
mental shifts in drug pricing.  First, 
will these shifts appropriately reduce the 
waste, fraud and abuse concerns that 
plagued Medicare and Medicaid in the 
past?  Second, how will these shifts 
affect access to quality care?  Finally, 
which solutions should be considered 
and/or implemented in order to en-
sure consistency and fairness with 
respect to drug pricing and reimburse-
ment? 
In response to the question of 
whether the switch to new drug reim-
bursement systems is justified, the 
answer appears to be “yes.”  Under 
Medicare Part B, the ASP system ap-
propriately reduced the waste, fraud 
and abuse concerns that occurred in 
the program under the old AWP sys-
tem.  For example, drug prices are 
now less likely to be inflated because 
they are based on actual sales data 
which is regularly reported to the gov-
ernment.  This is in contrast to the less 
transparent AWP system where the 
prices were self-determined by drug 
manufacturers in a more closed proc-
ess using data that was not defined by 
law or regulation.  Moreover, the ASP 
system decreased Medicare overpay-
ments through a reduction of the 
“spread” offered to physicians by in-
cluding most price concessions in the 
sales data. 
The change to the ASP system has not 
only reduced waste, fraud and abuse 
concerns, but it has also allowed con-
tinued access to quality care received 
by Medicare beneficiaries with respect 
to physician-administered drugs and 
services.  Although many feared that 
the ASP system would force physi-
cians to stop administering drugs due 
to lower reimbursement rates, physi-
cians have adjusted their practice pat-
terns and, in general, continue to enjoy 
profitability.  In order to ensure profit-
ability in the future, however, the gov-
ernment must continue to monitor 
and work with physician practices in 
regard to various aspects of their busi-
ness, such as negotiating lower drug 
prices. 
Similarly, the AMP system under 
Medicaid has responded to the waste, 
fraud and abuse concerns that the 
program was overpaying for drugs by 
relying on published prices that did  
See “Meta-Care” on Page 11 
‘Meta-Care’, Continued... 
ASP System 
Applies to drugs 
covered under 
Medicare Part B 
AMP System 
Applies to all 
drugs pur-
chased at retail           
pharmacies   
under Medicaid 
PAGE 9 VOLUME 1, ISSUE 1 
 
“TO CATCH THE READER'S ATTENTION, PLACE AN INTERESTING SENTENCE OR QUOTE FROM THE STORY HERE.” 
 
devices poses a health risk to patients 
and seventy-four percent of surgeons 
strongly believe that medical devices 
should not be reprocessed.  Hospitals 
claim that reusing devices saves a sub-
stantial amount of money and that 
there is no risk of harm because the 
devices are sterilized and are held to 
the highest standards.  
Ramifications of Medical Device 
Reuse 
Medical device reuse has become a 
much more serious issue than has 
been recognized in the past. In the 
United States, there are several docu-
mented cases with one major similar-
ity: the injured patient had a reused 
medical device implanted or used on 
him or her during a procedure. 
 
 
 
 
 
 
 
 
One glaring case that shows the po-
tential danger of reusing medical de-
vices involved patients who had un-
dergone brain surgeries.  A rarely seen 
medica l  condit ion known as 
Creutzfeldt-Jakob disease (CJD), 
which causes the deterioration of nor-
mal brain functions and eventually 
leads to death, was being seen more 
frequently in certain hospitals. The 
apparent cause of the increase in the 
number of cases was the fact that a 
surgical device used to relieve cranial 
pressure for one patient with CJD had 
been reused multiple times.  As a re-
sult, numerous  patients became in-
fected or had the possibility of later 
contracting this deadly disease.  
Peripheral problems associated with 
reused medical devices have also in-
creased in recent years.  One example 
is the growth of poorly regulated re-
processing companies. Originally, hos-
pitals would reprocess medical devices 
in-house.  Due to the FDA’s revised 
reprocessed device regulations, 
amended in 2000, hospitals have be-
gun contracting third-party reprocess-
ing companies to perform the service. 
In 2006, the reprocessing market was 
valued at $130 million. Growth ex-
perts project that by 2010 the market 
will be valued at over $200 million.   
Although hospitals claim that reusing 
devices saves tens of millions of dol-
lars a year, the Association of Device 
Manufacturers claims that “single use 
devices typically contain difficult-to-
access areas that create barriers to 
cleaning and permit blood, tissue, or 
other bodily fluids to contaminate the 
reprocessed device, allowing potential 
transmission of viral and bacterial 
infections.”  
To date, the FDA has no set number 
of inspectors assigned to reprocessing 
facilities.  Rather, the agency relies on 
doctors to voluntarily report problems 
with faulty medical devices, and facili-
ties are required to report deaths to 
the FDA, but not device malfunctions. 
Efforts to Reduce Medical Device 
Reuse at the Federal Level 
A number of measures have been 
taken which have helped minimize the 
number of devices that are reproc-
essed.  The Medical Device User Fee 
Act (MDUFA), which Congress re-
cently passed, requires the federal gov-
ernment to study and report the num-
ber of infections attributable to new or 
reused medical devices. This study will 
also examine the possible causes of 
these infections. 
In addition, the FDA now requires 
that all reprocessed SUDs entering 
into interstate commerce must 
“prominently and conspicuously” bear 
the statement: “Reprocessed Device 
for Single Use. Reprocessed By [name 
of manufacturer that reprocessed the 
device].” Another recent piece of leg-
islation, the Healthy Hospitals Act, 
requires hospitals to publicly report 
their infection rates.  The reporting 
gives patients an informed choice 
when selecting hospitals for care.  This 
Act also provides funding to the hos-
pital from the savings by reducing 
infection rates to zero. 
States Taking Action 
Currently, Massachusetts has a law 
that requires hospitals to obtain a pa-
tient’s informed consent regarding  the 
implanting of a reused medical device. 
Re-processors are saying that they 
would support such legislation nation-
wide as long as hospitals are also re-
quired to disclose the risks of new 
devices, thereby exposing all risks for  
See “Savings” on Page 11 
Savings, Continued... 
“SEVENTY-
FOUR PERCENT 
OF SURGEONS 
STRONGLY  
BELIEVE THAT 
DEVICES 
SHOULD NOT BE 
REPROCESSED.” 
Areas of Study Required Under 
MDUFA 
?? Whether infections were acquired 
from reprocessed SUDs 
?? Handling of medical devices 
?? In-hospital sterilization of medical 
devices 
?? Healthcare professional practices 
for patient examination and treat-
ment 
?? Hospital-based policies for infec-
tion control and prevention 
?? Hospital-based practices for han-
dling medical waste  
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Patent Practices, Continued... 
entability of an invention could cause 
future drug abandonment if return on 
investment was unlikely.  Essentially, 
GSK seems to argue that maintaining 
the status quo is the best way to avoid 
upsetting practices that favor innova-
tion. 
Potential Benefits of the New 
Rules 
Despite the claims of GSK and other 
large pharmaceutical companies of the 
potential to stifle innovation and dis-
courage investment, the new rules may 
actually prove to be advantageous to 
overall healthcare.  First, with poten-
tially weaker patent protection, generic 
drug companies could produce a ge-
neric version of drugs earlier, thus 
making medicines more readily avail-
able to the public. However, this argu-
ment clearly assumes that innovators 
continue to do the “heavy lifting” of 
new drug discovery and development 
with less incentive.  
Second, pharmaceutical companies 
could potentially maintain a similar 
amount of protection by modifying 
their patent prosecution strategies. 
The enormous market for innovator 
drugs should continue to provide an 
incentive for finding a workable solu-
tion.  Third, the USPTO claims that 
the rule changes are designed to make 
patent prosecution more efficient and 
reliable. If true, this would undoubt-
edly be a benefit to the pharmaceutical 
industry, which would receive the 
security of a granted patent at an ear-
lier stage of drug development. Fi-
nally, a different type of innovation 
may emerge.  The potentially greater 
freedom to explore the discoveries of 
others because of reduced exclusivity 
could actually increase the speed of 
innovation, by putting the less desir-
able pieces of the “next best thing” 
into the hands of a great number of 
separate innovators, decreasing the 
cycle time. Several businesses in the 
copyright sector already proactively 
embrace this concept through the 
“Creative Commons” movement, 
which eschews complete and exclusive 
copyright protection in favor of allow-
ing free selective uses.  This move-
ment seeks to offer a “best-of-both-
worlds way to protect” works, encour-
aging certain uses and declaring other 
rights reserved.  
Perhaps the pharmaceutical industry 
will follow suit as a consequence of 
the new patent limitations imposed on 
it.  Clearly, the new rules may affect 
the industry in any number of ways, 
not all of which lead to the death of 
innovator drugs. 
Current Status 
As a result of this controversy sur-
rounding the rule changes, particularly 
the pharmaceutical industry outrage as 
expressed by GSK, implementation 
has been put on hold.  On October 
31, 2007, the U.S. District Court for 
the Eastern District of Virginia 
granted the preliminary injunction 
filed by GSK in Tafas v. Dudas. With 
many patent practitioners waiting anx-
iously for a final decision, only time 
will tell if traditional discovery prac-
tices will continue to dominate or if 
the rule changes will require a new 
model, to the benefit or detriment of 
the American health care system. 
See Page 13 for Citations  
detrimental to health care innovation: 
“The scientific research and discovery 
of a new drug and the following clini-
cal development takes a decade or 
more of hard work and often a billion 
dollars in completely at-risk invest-
ment.”  
The company (and presumably others 
like it) simply “cannot afford to under-
take the huge investment” that is re-
quired to develop drugs without 
strong patent protection.  GSK even 
cites one estimate that investment in 
innovation “may ‘decrease by approxi-
mately [sixty percent]’ without ade-
quate patent protection.”  
With respect to continuation practice, 
GSK routinely returns to its initial 
patent application to select a new lead 
drug candidate after a first candidate 
fails in testing.  Under the new rules, 
filing a related follow-on patent to 
protect this new selection would not 
be permitted (despite the fact that the 
continuing application does not in-
crease the period of market exclusiv-
ity).  Without strong patent protection 
on the drug molecule, GSK would 
have little incentive to develop the 
second new molecule.  This practice 
pervades the industry; from 1996-
1998, only 7.8% of patents filed were 
pharmaceutical, while the industry 
accounted for twenty-two percent of 
continuation applications.  
With respect to claim limitations, inde-
pendent research has shown that 
thirty-five percent of “important pat-
ents” (involved in patent litigation) in 
all fields since 2002 contain more than 
twenty-five claims. Although GSK 
does not thoroughly address this issue, 
the same concept of creating incentive 
to innovate via strong (and perhaps 
broad and flexible) patent protection 
would presumably apply to claim limi-
tations; any limitation on the pat-
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the public for use by the states as the 
basis for setting drug reimbursement. 
Other government responses, how-
ever, may be less successful.  For in-
stance, the formula and calculation of 
the “Federal Upper Limit” may signifi-
cantly harm the profitability of phar-
macies due to below-cost reimburse-
ment.  The “Federal Upper Limit” 
refers to the maximum amount Medi-
caid will reimburse certain drugs 
(because it is capped by the Centers 
for Medicare and Medicaid Services).  
Finally, although it is too early to 
evaluate whether the new AMP system 
(which was slated to go into effect 
January 1, 2008, before a judicial in-
junction prevented its full implemen-
tation) negatively impacts access to 
quality care for Medicaid beneficiaries, 
the large presence of pharmacies 
throughout the country suggests that 
access to drugs will not suffer.  It is 
unlikely that lower reimbursement 
rates will cause pharmacies to shut 
down.  The pharmacy industry should 
take comfort in healthcare history 
because the fears surrounding the new 
AMP system mirror the fears (which 
not accurately reflect pharmacy acqui-
sition costs.  The government has 
implemented several policies which 
attempt to ensure that drug prices 
more accurately reflect the cost for 
pharmacies to acquire the drugs.  For 
instance, the revised AMP definition 
helps drug manufacturers decipher 
which type of sales the companies 
should include in their AMP determi-
nations, thereby lowering reimburse-
ment rates.  In addition, the new re-
porting requirements promote trans-
parency within the drug pricing sys-
tem.  These reports show how manu-
facturers determine the price of their 
drugs and make that data available to 
later turned out to be largely untrue) 
that surrounded the implementation 
of the ASP system.  Just as physicians 
changed their practice patterns under 
the ASP system, it is likely that phar-
macies, too, will alter their business 
models to accommodate the shift in 
reimbursement with the new AMP 
system.  In doing so, pharmacies will 
continue making profits through gov-
ernment reimbursement rates of drugs 
that accurately reflect pharmacy acqui-
sition costs.   
Ultimately, the ASP and revised AMP 
systems will save taxpayer money that 
has been spent on inaccurately priced 
drugs and limit the damage of reduced 
profits in the healthcare industry.  The 
foregoing analysis is even more signifi-
cant when considering that this suc-
cess foreshadows the likely adoption 
of the new reimbursement systems by 
private payers in the coming years. 
See Page 13 for Citations  
For a more in-depth paper on this 
topic, please contact Marc Adler at 
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‘Meta-Care,’ Continued... 
both new and reused devices. 
Recommendations 
Along with obtaining patient consent, 
there are several solutions to alleviate 
some of the major problems associ-
ated with medical device reuse.  First, 
the FDA should enhance the system 
created to determine the amount of 
infections from reused SUDs and 
eliminate reuse in medical devices with 
an unusually high infection rate.  Sec-
ond, health care providers need to 
begin to work with medical device 
companies to inform patients of 
whether or not they are obtaining a 
reused medical device. 
Patients have the right to know 
whether a SUD has already been im-
planted or used on another patient 
before the device is used on them.   
Finally, for a modest fee, patients 
should be able to request a new device 
for implantation.  Otherwise, patients 
are subject to the possibility of being 
exposed to an unnecessary risk of 
hospital-acquired infections and medi-
cal device failures. 
Medical device reuse is a national issue 
of concern that must be addressed. 
Through the help of the FDA and 
other government agencies, this prob-
lem is slowly but surely coming to the 
forefront of our nation’s healthcare 
issues and will hopefully be resolved. 
See Page 12 for citations 
Savings, Continued... 
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Commission, Continued... 
Finally, the Commission Report raises 
certain reform possibilities that it does 
not actually recommend. It suggests 
that economic credentialing might ame-
liorate the phenomenon of physicians 
referring easy insured cases to ambula-
tory centers but difficult, risky or unin-
sured cases to hospitals, but then specu-
lates that such a policy would result in 
litigation.  Similarly, the Report raises 
the spectre of replacing the extant price-
discriminatory system of hospital pric-
ing with a uniform all-payer system, but 
ultimately demurs on the issue, lament-
ing that it is outside the scope of its 
enabling executive order.   
Conclusion 
New Jersey’s brand new Commis-
sioner of Health & Senior Services, 
Heather Howard, who received the 
Report on behalf of the Governor, is 
apparently the primary person respon-
sible for implementing its recommen-
dations, but no new money has been 
identified to support the Commis-
sion’s recommendations — not even 
for the Distressed Hospital Program.  
Her problems will be exacerbated if 
anything resembling the current 
budget proposal becomes law — it 
proposes cuts of $3 billion in federal 
funding to New Jersey hospitals over 
the next five years. 
See Page 13 for Citations  
consultants to compare the efficiency 
of New Jersey hospitals to national 
and regional benchmarks, the results 
of which the state could employ in 
effectuating a new methodology for 
Medicaid and Charity Care reimburse-
ment.  In response to the inefficien-
cies created by the misalignment of 
hospital-physician financial incentives, 
the Report urges the state to consider 
a range of strategies, including physi-
cian reimbursement based upon sever-
ity-adjusted DRG or Relative Value 
Units, physician rewards based upon 
systemic cost savings, and the align-
ment of financial incentives and liabil-
ity exposure. 
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?? Civil commitment of sex 
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Valentine’s Day Blood Drive 
Health Law Forum News 
Newark, NJ — February 14, 2008 
The turnout was great, even for a chilly 
day in February.  Members of Health 
Law Forum, along with the Public In-
terest Network and Environmental Law 
Society, organized a successful drive 
that touted the slogan “Have a Heart, 
Donate Blood.” 
Bandaged Students enjoy post-donation 
snacks. 
Nurses and medical assistants from 
New Jersey Blood Services skillfully 
drew blood while members of the three 
student groups cheerfully manned the 
table, donated blood, and handed out 
Valentine’s Day candy to students and 
faculty.  The day went smoothly with  
In true law school fashion, a student reads 
while donating. 
no mishaps, as indicated by one 
nurse’s comment on her gratitude 
that “the fire alarm didn’t go off again 
like last year.” 
Of the 65 donors present, 57 were 
able to give blood and help save lives 
in New Jersey and around the coun-
try. The drive was a success due to 
the dedication and enthusiasm of the 
students at Seton Hall and the staff of 
NJ Blood Services. 
Rationalizing Health Care in New Jersey: A Discussion 
Newark, NJ — March 11, 2008 
The Seton Hall Law School Health Law 
Forum and Seton Hall Health Law and 
Policy Program recently hosted the 
New Jersey Commissioner of Human 
Services, Jennifer Velez.  
Commissioner Velez spoke about the 
findings and Recommendations in the 
Final Report of the New Jersey Commis-
sion on Rationalizing Health Care Resources. 
The event was attended by over 80 par-
ticipants, including students, faculty, 
and members of the community. 
Commissioner Velez with members of the 
Health Law Forum’s Executive Board 
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About the Health Law Forum 
The Health Law Forum (HLF) is a student      
organization at Seton Hall Law School for 
those interested in health law.   
The Health Law Forum hosts speakers, 
panel discussions, community service 
projects, and networking events through-
out each academic year.  
The Health Law Advocates (HLA), an HLF     
sub-group for students interested in 
health policy, hosts monthly round-table 
discussions about current topics in the 
healthcare field. 
Shelly Weizman’s interest in health policy lies in its intersection with a wide range of legal 
and social issues, including access to health care and other benefits, mental illness and addic-
tion, homelessness, physical disabilities, and special education.  Her professional goal is to 
promote systemic reform for underserved populations. 
Student Contributors 
Christina Hage’s interest in the health care arena focuses primarily on issues regarding phar-
maceutical and medical device marketing. Christina has interned at the New Jersey Attorney 
General’s Office, the Honorable Judge Issenman’s Chambers, and Saint Peter's University 
Hospital. This summer she will serve as a summer associate at Wolf Block located in Rose-
land, New Jersey.  
Prior to coming to Seton Hall, Sarah Geers worked as a Pharmaceutical Scientist at Merck in 
Rahway, New Jersey.  As part of her research career, she developed clinical trial and mar-
keted drugs and investigated new formulation technologies, which led to an internship in the 
Patent Department.  This summer she will be returning to the Merck Patent Department.   
Marc Adler has served as a legal extern at the University of Medicine and Dentistry of NJ, 
and is currently employed part-time as an associate at R-Squared, a consulting firm that 
works with a variety of healthcare and life sciences organizations.  Marc has authored nu-
merous legal papers, which are pending publication in the Bureau of National Affairs and the 
Journal of Legal Medicine. He has also won first place in the national writing competition spon-
sored by the American College of Legal Medicine. 
Nicole Ho worked as a research associate at Merck Research Labs and Bristol-Myers Squibb 
prior to law school. Nicole received the Merck Patent Fellowship and will be working as an 
intern at the patent office at Merck and Co., Inc. Nicole is a member of the Seton Hall 
Health Law Forum and Health Law Advocates.    
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